Express Scripts (ESRX) Rating Increased to Buy at ValuEngine

Express Scripts (NASDAQ:ESRX) was upgraded by research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued on Monday.

Several other equities research analysts also recently weighed in on the company. Robert W. Baird reaffirmed a “hold” rating and set a $56.00 price target on shares of Express Scripts in a report on Friday, September 1st. Jefferies Group set a $72.00 price target on Express Scripts and gave the stock a “buy” rating in a report on Tuesday, August 29th. Raymond James Financial reaffirmed an “underperform” rating on shares of Express Scripts in a report on Monday, October 9th. Zacks Investment Research downgraded Express Scripts from a “buy” rating to a “sell” rating in a report on Tuesday, October 24th. Finally, Royal Bank Of Canada set a $66.00 price target on Express Scripts and gave the stock a “hold” rating in a report on Wednesday, October 25th. Six investment analysts have rated the stock with a sell rating, ten have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $70.67.

Express Scripts (ESRX) opened at $67.84 on Monday. The company has a current ratio of 0.73, a quick ratio of 0.61 and a debt-to-equity ratio of 0.86. The stock has a market cap of $38,603.98, a P/E ratio of 9.96, a PEG ratio of 1.01 and a beta of 0.88. Express Scripts has a 1 year low of $55.80 and a 1 year high of $77.25.

Express Scripts (NASDAQ:ESRX) last announced its earnings results on Tuesday, October 24th. The company reported $1.90 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.90. Express Scripts had a net margin of 3.64% and a return on equity of 25.46%. The business had revenue of $24.68 billion for the quarter, compared to analyst estimates of $25.68 billion. During the same period last year, the firm posted $1.74 earnings per share. The company’s revenue for the quarter was down 2.9% compared to the same quarter last year. research analysts predict that Express Scripts will post 7.01 EPS for the current year.

In other news, Director Woodrow A. Myers, Jr. sold 3,900 shares of the firm’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $63.93, for a total value of $249,327.00. Following the completion of the transaction, the director now owns 11,500 shares in the company, valued at $735,195. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, VP Phyllis S. Anderson sold 643 shares of the firm’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $62.37, for a total value of $40,103.91. The disclosure for this sale can be found here. In the last three months, insiders sold 5,121 shares of company stock valued at $325,920. 0.68% of the stock is owned by corporate insiders.

Several hedge funds have recently made changes to their positions in the company. Chicago Partners Investment Group LLC increased its position in shares of Express Scripts by 374.2% in the third quarter. Chicago Partners Investment Group LLC now owns 4,766 shares of the company’s stock valued at $302,000 after buying an additional 3,761 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new position in shares of Express Scripts in the third quarter valued at $467,000. Optimum Investment Advisors increased its position in Express Scripts by 64.7% during the 3rd quarter. Optimum Investment Advisors now owns 5,471 shares of the company’s stock worth $346,000 after purchasing an additional 2,150 shares in the last quarter. Wealthsource Partners LLC purchased a new stake in Express Scripts during the 3rd quarter worth about $224,000. Finally, Iguana Healthcare Management LLC purchased a new stake in Express Scripts during the 3rd quarter worth about $1,583,000. Institutional investors and hedge funds own 88.44% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://stocknewstimes.com/2017/12/06/express-scripts-esrx-rating-increased-to-buy-at-valuengine.html.

Express Scripts Company Profile

Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).

Analyst Recommendations for Express Scripts (NASDAQ:ESRX)

Receive News & Ratings for Express Scripts Holding Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts Holding Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply